The Invisible Costs of Cancer Treatment: Quantifying Non‐Medical Economic Consequences for Cancer Survivors Undergoing Systemic and Radiation Therapies
Cancer Medicine · 2025
DOI: 10.1002/cam4.71309 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Md Shahjalal und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health, North South University, Dhaka, Bangladesh. Hauptthemen laut MEDLINE: Cancer Survivors, Neoplasms, Cost of Illness. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Background
The non‐medical economic consequences of cancer on individuals and families in low‐ and middle‐income countries, including Bangladesh, remain poorly quantified. This study measures the non‐medical economic consequences of cancer survivors and their families, including sacrifices in essential family consumption, social participation and family members' schooling.
Methods
We conducted a cross‐sectional survey between January and May 2022, involving 607 adult patients receiving cancer treatment at two tertiary specialised cancer hospitals in Bangladesh. Participants reported any occurrence of non‐medical economic consequences: reduction in essential goods (REG) consumption, avoidance of social events (ASE) and cessation of schooling (CS) of family members. We used a multivariable logistic regression model to assess the associations between each non‐medical economic consequence and clinical and socioeconomic factors. Additionally, we fitted a Poisson regression to model the count of non‐medical economic consequence events as a function of disease stage and relevant covariates.
Results
Overall, 39% of patients reported REG, 36% ASE, and 38% CS. After adjusting for co‐variates, advanced cancer (stage IV) was a significant predictor of non‐medical economic consequence (REG: OR = 5.58, 95% CI 0.99–31.44, p = 0.051; ASE: 11.35, 1.81–71.07, p = 0.009; SS: 101.56, 2.47–4173.90, p = 0.015) compared with early cancer (stage I). Compared with the highest‐income families, patients from low‐ and lower‐middle‐income families had significantly higher odds of experiencing all outcomes (REG: OR = 7.57, 3.01–19.06, p < 0.001 and 7.23, 1.81–28.89, p = 0.005; ASE: 10.21, 3.81–27.36, p < 0.001 and 17.99, 4.26–75.96, p < 0.001; CS: 11.37, 3.23–40.00, p < 0.001 and 12.58, 1.90–83.19, p = 0.009). Employed patients were also at markedly higher risk, with substantially increased odds of REG (18.27 times), ASE (41.01 times) and CS (72.34 times) compared with non‐employed patients (all p < 0.01).
Conclusion
Cancer treatment in Bangladesh imposes substantial and inequitable non‐medical economic consequences, disproportionately affecting patients with advanced‐stage cancer, lower‐income families and those in active employment. Policymakers may prioritise strengthening early cancer detection programs, expanding targeted financial protection schemes and introducing workplace and educational support mechanisms to safeguard family welfare and promote more equitable outcomes during cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Public Health, North South University, Dhaka, Bangladesh.
- Research Rats, Dhaka, Bangladesh.
- School of Health, Medical and Applied Sciences, Central Queensland University, Rockhampton, New South Wales, Australia.
- Appleton Institute, Physical Activity Research Group, Central Queensland University, Rockhampton, Queensland, Australia.
- School of Business, Faculty of Business, Education, Law and Arts, University of Southern Queensland, Toowoomba, Queensland, Australia.
- Centre for Health Research, University of Southern Queensland, Toowoomba, Queensland, Australia.
ORCID-Profile: Md Shahjalal, Edward Christopher Dee, Rashidul Alam Mahumud
Förderung
- NCI NIH HHS
Zitieren
APA
Shahjalal, M., Dahal, P. K., Mosharaf, M. P., Chen, Y., Azmary, M., Dee, E. C., Alam, K., & Mahumud, R. A. (2025). The Invisible Costs of Cancer Treatment: Quantifying Non‐Medical Economic Consequences for Cancer Survivors Undergoing Systemic and Radiation Therapies. Cancer Medicine. https://doi.org/10.1002/cam4.71309
Vancouver
Shahjalal M, Dahal PK, Mosharaf MP, Chen Y, Azmary M, Dee EC, et al. The Invisible Costs of Cancer Treatment: Quantifying Non‐Medical Economic Consequences for Cancer Survivors Undergoing Systemic and Radiation Therapies. Cancer Medicine. 2025. doi:10.1002/cam4.71309
BibTeX
@article{Shahjalal2025,
author = {Shahjalal, Md and Dahal, Padam Kanta and Mosharaf, Md Parvez and Chen, Yifu and Azmary, Mohoua and Dee, Edward Christopher and Alam, Khorshed and Mahumud, Rashidul Alam},
title = {The Invisible Costs of Cancer Treatment: Quantifying Non‐Medical Economic Consequences for Cancer Survivors Undergoing Systemic and Radiation Therapies},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.71309}
}
EUVIMED